@article{18d5ed55feb14d92b48c69221552cac0,
title = "Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis",
abstract = "Background: Electroconvulsive therapy (ECT) is a well-established treatment for psychiatric disorders, including depression and psychosis. ECT has been reported to be effective in treating such psychiatric symptoms in patients with Parkinson's disease (PD) and has been also reported to be effective in treating motor symptoms. The aim of the study is to summarize previous clinical studies investigating the efficacy of ECT for symptoms in patients with PD. Methods: A systematic review and meta-analysis of any study designs assessing motor and/or non-motor symptoms in patients with PD before and after ECT. Co-primary outcomes were set as motor manifestations assessed using the Unified Parkinson's Disease Rating Scale or other rating scales, and non-motor symptoms included depression and psychosis. Secondary outcomes were wearing-off phenomenon and cognitive function. The impact of ECT on those symptoms was examined by comparing the severity of the symptoms before and after ECT using a random effect model and was expressed in standardized mean difference. Results: Of 1219 identified citations, 14 studies (n = 129; 1 randomized controlled study, 9 prospective observational studies, and 4 retrospective studies) were analyzed. The findings were as follows: ECT significantly improved motor manifestations in patients with PD, and the improvement was significant in the subpopulation without psychiatric symptoms; ECT significantly improved depression and psychosis; and ECT significantly relieved wearing-off phenomenon and did not worsen cognitive functioning. Conclusion: The current meta-analysis suggests the potential benefit of ECT on motor and non-motor symptoms in presumably complicated and difficult-to-treat subgroups.",
keywords = "Parkinson's disease, depression, electroconvulsive therapy, meta-analysis, psychosis",
author = "Akihiro Takamiya and Morinobu Seki and Shun Kudo and Takahito Yoshizaki and Jin Nakahara and Masaru Mimura and Taishiro Kishimoto",
note = "Funding Information: S.K. and T.Y. have nothing to declare. A.T. has received grants from Keio University Medical Science Fund and Kanae Foundation for the Promotion of Medical Science. M.S. has received grants from Takeda Japan Medical Affairs Funded Research Grant 2018 and Kanae Foundation for the Promotion of Medical Science. J.N. has received honoraria from AbbVie, Alexion, Astellas, Biogen, CSL‐Behring, Daiichi Sankyo, Eisai, Fujimoto Pharma, JB, Mitsubishi‐Tanabe, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, Sumitomo Dainippon Pharma, and Takeda. J.N. has received grants‐in‐aid from the Japanese government (MEXT and AMED); grants‐in‐aid from Keio University; a collaborative research grant from Biogen; and research scholarships from Astellas, B{\"o}ehringer‐Ingelheim, Daiichi Sankyo, Eisai, JB, Kyowa‐Kirin, Mitsubishi‐Tanabe, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Sanofi, Shionogi, and Sumitomo Dainippon Pharma. J.N. is also an advisory board member of Biogen and Novartis Pharma. M.M. has received grants and speaker's honoraria from Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past 12 months. T.K. has received consultant fees from Otsuka Pharmaceutical, Pfizer, and Sumitomo Dainippon Pharma and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo Pharma, Janssen Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, and Pfizer. Publisher Copyright: {\textcopyright} 2020 International Parkinson and Movement Disorder Society",
year = "2021",
month = jan,
doi = "10.1002/mds.28335",
language = "English",
volume = "36",
pages = "50--58",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",
}